Liquid Biopsies for Detecting Somatic Mutations in Sporadic Cerebral Arteriovenous Malformations.

NCT ID: NCT07103304

Last Updated: 2025-09-08

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 16 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-09-01
• Study Completion Date: 2028-04-01

Brief Summary

Cerebral arteriovenous malformations (CAVMs) are abnormal vessels located on the surface of the brain or within the cerebral parenchyma, causing abnormal communication between the arterial and venous networks, without the interposition of the capillary bed. The main risk associated with these malformations is rupture, which causes intracranial bleeding and can lead to serious sequelae or even death. CAVMs (except those of clearly identified genetic origin [< 5%], such as mutations associated with Rendu-Osler disease) have long been considered to be of non-genetic origin.

However, somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway have recently been identified in surgical specimens of cAVMs. Furthermore, targeted inhibition of this pathway is effective in treating these malformations in animals and appears to be effective in extracranial arteriovenous malformations, particularly superficial ones.

Detailed Description

Next-generation sequencing of circulating DNA in liquid biopsies is a promising new and minimally invasive approach for studying the presence of mutations in arteriovenous malformations.

The goal of treating a cAVM is to obliterate the malformation in order to prevent or avoid the risk of haemorrhage. Several therapeutic modalities may be used, which can be combined: microsurgery, endovascular embolisation, and/or radiosurgery. However, these are invasive treatments that are not without risk.

The detection of mutations by liquid biopsies would enable the development of targeted, non-invasive drug therapies against these cAVMs.

The population consists of patients aged 18 years or older with cAVMs, for whom treatment by venous embolisation was recommended during a multidisciplinary consultation meeting.

This research focuses on identifying somatic genetic mutations that activate the RAS/RAF/MEK/ERK (MAPK) signalling pathway in cAVMs. These mutations have already been identified in surgical specimens. This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of cAVMs and the prevalence of each mutation.

These liquid biopsies will be performed during embolisation surgery by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to usual care).

Conditions

Cerebral Arteriovenous Malformations

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Search for activating somatic genetic mutations

This research aims to evaluate the genetic mutations identified by liquid biopsies on the drainage vein of AVMs, and the prevalence of each mutation.

These liquid biopsies will be performed during the embolisation procedure by sampling the drainage vein of the malformation and peripheral venous blood (no additional procedures compared to standard care).

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Treated for cAVM
• Indication for embolisation treatment decided upon during a multidisciplinary team meeting (MDT)
• Venous embolisation, with or without arterial embolisation
• Patients informed about the study and willing to participate

Exclusion Criteria

• Extra-cerebral arteriovenous malformations
• Under legal protection measures (guardianship/curatorship, etc.)
• Pregnancy
• Not eligible for intravenous treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Rouen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University Hospital of Caen

Caen, , France

Hôpital la Pitié-Salpêtrière

Paris, , France

University Hospital of Rouen

Rouen, , France

Countries

France

Central Contacts

Julien JB BUREL, Doctor

Role: CONTACT

Julien.Burel@chu-rouen.fr

02 32 88 88 50 ext. +33

Vincent VF FERRANTI, ARC

Role: CONTACT

Vincent.Ferranti@chu-rouen.fr

02 32 88 82 65 ext. +33

Facility Contacts

Charlotte CB BARBIER, Doctor

Role: primary

barbier-ch@chu-caen.fr

02 31 06 46 97 ext. +33

Frederic FC CLARENCON, Professor

Role: primary

frederic.clarencon@aphp.fr

01 42 16 55 45 ext. +33

Julien JB BUREL, Doctor

Role: primary

Julien.Burel@chu-rouen.fr

02 32 88 88 50 ext. +33

Other Identifiers

N° IDRCB : 2025-A00757-42

Identifier Type: OTHER

Identifier Source: secondary_id

2023/0310/OB

Identifier Type: -

Identifier Source: org_study_id